Scarica l'app Stockscreener
1,273.46
2.54%
-33.23
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$1,306.69
Aprire:
$1304.15
Volume 24 ore:
2.27M
Relative Volume:
0.94
Capitalizzazione di mercato:
$1.14T
Reddito:
$72.25B
Utile/perdita netta:
$25.28B
Rapporto P/E:
45.84
EPS:
27.781
Flusso di cassa netto:
$10.37B
1 W Prestazione:
+1.31%
1M Prestazione:
+10.64%
6M Prestazione:
+38.77%
1 anno Prestazione:
+55.10%
Intervallo 1D:
$1,257.62
$1,307.92
Intervallo di 1 settimana:
$1,239.10
$1,321.21
Portata 52W:
$806.02
$1,321.21
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,273.46 | 1.14T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
263.81 | 635.07B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
285.64 | 504.76B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
145.27 | 358.41B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
151.12 | 287.24B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-15 | Aggiornamento | Berenberg | Hold → Buy |
| 2026-03-17 | Downgrade | HSBC Securities | Hold → Reduce |
| 2026-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-02-20 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-12-16 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | Reiterato | BofA Securities | Buy |
| 2025-12-15 | Reiterato | Goldman | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-10 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Reiterato | BMO Capital Markets | Outperform |
| 2025-10-14 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-09-17 | Downgrade | Berenberg | Buy → Hold |
| 2025-08-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Downgrade | Erste Group | Buy → Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Facing Investing Fears - The Motley Fool
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Zacks Investment Research
Why Healthcare ETFs Are Hovering Around One-Year Highs - Zacks Investment Research
Should Defiance Large Cap ex-Mag 7 ETF (XMAG) Be on Your Investing Radar? - Zacks Investment Research
Roche's 9M 2026 Sales Rise on Strong Drug Demand, Pipeline Advances - Zacks Investment Research
Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight - GlobeNewswire Inc.
Eli Lilly breaks ground on $5 billion production plant in Goochland - Richmond Times-Dispatch
NVO vs. VKTX: Which Obesity Stock Could Deliver Bigger Gains? - Zacks Investment Research
Eli Lilly and Co Stock (LLY) Moved Up by 3.37% on Oct 22: What Investors Need To Know - TradingKey
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination - Reuters
Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility - The Motley Fool
Eli Lilly Stock Is Up 18% This Year. Is It Still a Buy Ahead of Earnings? - Morningstar
RBC Capital Remains a Buy on Eli Lilly & Co (LLY) - The Globe and Mail
Vanguard Health Care ETF vs iShares U.S. Healthcare ETF - The Motley Fool
If You Invested $100 In Eli Lilly Stock 20 Years Ago, You Would Have This Much Today - Benzinga
Where Will Novo Stock Be in 10 Years? - The Motley Fool
Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight - GlobeNewswire Inc.
Eli Lilly stock: Barclays maintains USD 1,400.00 target - AD HOC NEWS
Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026 - The Motley Fool
LLY Stock Alert: What to Know as Eli Lilly Hits a New All-Time High - Barchart.com
How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results? - Zacks Investment Research
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know - Zacks Investment Research
Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock? - The Motley Fool
Bet on This New GLP-1 ETF to Gain Exposure to a Booming Market - Zacks Investment Research
Eli Lilly and Co (LLY.HA) stock price, news, quote and history - Yahoo Finance UK
Should You Invest in the Vanguard Health Care Index Fund ETF Shares (VHT)? - Zacks Investment Research
Goldman Sachs raises Lilly target to USD 1,413: Eli Lilly and Co. stock falls 1.53 percent - AD HOC NEWS
Eli Lilly and Co. stock: Goldman lifts target to USD 1,413, falls pre-market - AD HOC NEWS
Here's What I'm Planning With My Eli Lilly Position - The Motley Fool
Eli Lilly & Co. stock outperforms competitors on strong trading day - MarketWatch
If Eli Lilly Grows At 10% a Year, Here’s What $1,000 Becomes By 2030 - Yahoo Finance
Eli Lilly and Co Stock (LLY) Opened Up by 5.01% on Oct 20: A Full Analysis - TradingKey
GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth - Zacks Investment Research
Eli Lilly confirms October 29 results. Eli Lilly stock trades 1.79 percent below its high - ad-hoc-news.de
Genome & Company Joins Eli Lilly's AI Drug Discovery Platform - Seoul Economic Daily
Prelude Partners With Lilly to Test Breast Cancer Drug Combinations - MyChesCo
Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts - Zacks Investment Research
Eli Lilly Is Cracking Down on an Experimental Weight-Loss Drug. Georgia Clinics Are Promoting It Anyway - Inc.com
One holder reports sole voting power over 90.1M Eli Lilly (LLY) shares. - Stock Titan
Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight - GlobeNewswire Inc.
Eli Lilly Plans Pediatric Omvoh Expansion After Phase 3 Trial Wi - GuruFocus
Is Eli Lilly Stock a Buy Right Now? - The Motley Fool
Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market - Yahoo Finance
Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market - The Motley Fool
HK-listed Metis TechBio, Eli Lilly strike drug-delivery deal worth up to $1.1 billion - Reuters
Can Eli Lilly’s Growth Keep Justifying its Premium? - Yahoo Finance
Pfizer's Non-Oncology Performance in Q3: Driving Factors to Watch - Zacks Investment Research
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 Results? - Zacks Investment Research
METiS TechBio Partners with Eli Lilly (LLY) to Advance Lipid Nan - GuruFocus
Eli Lilly & Co (NYSE:LLY) Offers Dividend Quality for Growth-Focused Income Investors - ChartMill
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lilly Eli Co Azioni (LLY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| LILLY ENDOWMENT, INC. | Shareholder |
Oct 07 '26 |
Proposed Sale |
1,157.49 |
300,000 |
347,247,000 |
0 |
| Jonsson Patrik | EVP & President, LLY Int'l |
Aug 17 '26 |
Sale |
1,175.10 |
6,500 |
7,638,150 |
54,147 |
| Patrik Jonsson | Officer |
Aug 17 '26 |
Proposed Sale |
1,175.10 |
6,500 |
7,638,150 |
0 |
| DONALD ZAKROWSKI | Officer |
Aug 10 '26 |
Proposed Sale |
1,185.71 |
2,000 |
2,371,420 |
0 |
| Zakrowski Donald A | SVP, Finance, & CAO |
Aug 10 '26 |
Sale |
1,185.01 |
2,000 |
2,370,020 |
1,526 |
| Hakim Anat | EVP, GC & Secretary |
Aug 07 '26 |
Sale |
1,190.00 |
5,000 |
5,950,000 |
11,875 |
| Hakim Anat | Officer |
Aug 07 '26 |
Proposed Sale |
1,190.00 |
10,000 |
11,900,000 |
0 |
| Seymour Melissa | EVP, Global Quality |
Aug 01 '26 |
Option Exercise |
0.00 |
981 |
0 |
1,506 |
| LILLY ENDOWMENT, INC. | Shareholder |
Jul 07 '26 |
Proposed Sale |
1,200.06 |
310,000 |
372,018,600 |
0 |
| LILLY ENDOWMENT, INC. | Shareholder |
Jun 26 '26 |
Proposed Sale |
1,127.69 |
305,000 |
343,945,450 |
0 |
1.42%
0.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):